Skip to main content
. 2018 Jun 14;6(2):144–155. doi: 10.1093/nop/npy019

Table 5.

Multivariate Analysis

Median age Median interval (months) Total EQD2 (Gy) Re-irradiation EQD2 (Gy) Dose per fraction (Gy) PTV (ml) Type
Model 1 (MOS) 0.08-month decreased survival [95% CI, 0.03–0.13 months less]
P = .0019
0.25-month increased survival [95% CI, 0.02–0.3 months greater]
P < .0001
0.03-month increased survival [95% CI, 0.01–0.04 months greater]
P = .0004
- - 0.014-month decreased survival [95% CI, 0.01–0.02 months less]
P < .0001
*Conventional as reference
SRS 3.8 month increased survival [95%CI, 3.0–4.6 months greater]
FSRT 1.5 month increased survival [95%CI, 0.9–2.2 months greater]
P < .0001
Model 2 (MOS) 0.02-month decreased survival [95% CI, 0.02–0.07 months less]
P = .30 [Non-confounder]
0.28-month increased survival [95% CI, 0.24–0.32 months greater]
P < .0001
- 0.014-month decreased survival [95% CI, 0.0003 months greater–0.03 less]
P = .055 [Confounder]
- 0.014-month decreased survival [95% CI, 0.01– 0.02 months less]
P < .0001
*Conventional as reference
SRS 3.2 months increased survival [95%CI, 2.5–4.0 months greater]
FSRT 1.2 months increased survival [95%CI 0.5–1.8 months greater]
P < .0001
Model 3 (MOS) 0.02-month decreased survival [95% CI, 0.07 months less–0.02 greater]
P = .28 [Non-confounder]
0.28-month increased survival [95% CI, 0.24–0.32 months greater]
P < .0001
- - 0.04-month decreased survival [95% CI, 0.1 months less– 0.03 greater
P = .34 [Confounder]
0.014-month decreased survival [95% CI, 0.01–0.02 months less]
P < .0001
*Conventional as reference
SRS 3.2 months increased survival [95%CI, 2.1–4.3 months greater]
FSRT 1.1 months increased survival [95%CI, 0.5–1.8 months greater]
P < .0001
Model 4 (RN) 0.37% decreased rate [95% CI, 0.3–0.41 less]
P < .0001
0.23% decreased rate [95% CI, 0.19–0.27 less]
P < .0001
0.10% increased rate [95% CI, 0.09–0.11 greater]
P < .0001
- - 0.01% decreased rate [95%CI 0.009–0.013 less]
P < .0001
*Conventional as reference
SRS 0.4% increased rate [95%CI, 0.2–1.0% greater]
FSRT 4% increased rate [95%CI, 3.4 to 4.4 greater]
P < .0001
Model 5 (RN) 0.78% decreased rate [95% CI, 0.73–0.84 less]
P < .0001
0.48% decreased rate [95% CI, 0.42–0.55 less]
P < .0001
- 0.03% increased rate [0.01– 0.05% greater]
P ≤.0005
- 0.01% decreased rate [95%CI 0.007–0.014 less]
P < .0001
*Conventional as reference
SRS 5.0% increased rate [95%CI, 4.1–5.9 greater]
FSRT 6.0% increased rate [95% CI, 5.3–6.8 greater]
P < .0001
Model 6 (RN) 0.78% decreased rate [95% CI, 0.72–0.84 less]
P < .0001
0.48% decreased rate [95% CI, 0.42–0.54 less]
P < .0001
- - 0.03% decreased rate [95% CI, 0.13% less-0.06% greater]
P = .43 [Confounder]
0.01% decreased rate [95% CI, 0.009–0.015 less]
P < .0001
*Conventional as reference
SRS 4.5% increased rate [95%CI, 3.2–5.9% greater]
FSRT 5.8% increased rate [95%CI, 5.0–6.6% greater]
P < .0001